JP2016190843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016190843A5 JP2016190843A5 JP2016079689A JP2016079689A JP2016190843A5 JP 2016190843 A5 JP2016190843 A5 JP 2016190843A5 JP 2016079689 A JP2016079689 A JP 2016079689A JP 2016079689 A JP2016079689 A JP 2016079689A JP 2016190843 A5 JP2016190843 A5 JP 2016190843A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- halo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000001475 halogen functional group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229910052757 nitrogen Chemical group 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- -1 benzo [1,3] dioxolyl Chemical group 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 0 *C(**N1CC(C*C2)C2C1)=CN=C(C(CC1)=I)NC1=O Chemical compound *C(**N1CC(C*C2)C2C1)=CN=C(C(CC1)=I)NC1=O 0.000 description 20
- NTCIVFVXQRQTMS-LOACFLACSA-N C#CN1C[C@H](CN(C2)C(/C=C/c3cc(CCC(N4)=O)c4nc3)=O)[C@H]2C1 Chemical compound C#CN1C[C@H](CN(C2)C(/C=C/c3cc(CCC(N4)=O)c4nc3)=O)[C@H]2C1 NTCIVFVXQRQTMS-LOACFLACSA-N 0.000 description 1
- JWUUPDKWHPKBFF-RCQLRVLXSA-N C/C=C(/C)\C(\C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=C/C Chemical compound C/C=C(/C)\C(\C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=C/C JWUUPDKWHPKBFF-RCQLRVLXSA-N 0.000 description 1
- STVWBNMXXSCBFH-GORDUTHDSA-N CC(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O Chemical compound CC(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O STVWBNMXXSCBFH-GORDUTHDSA-N 0.000 description 1
- KELVAMQBGKMJHU-GORDUTHDSA-N CC(c([s]cc1)c1C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)O Chemical compound CC(c([s]cc1)c1C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)O KELVAMQBGKMJHU-GORDUTHDSA-N 0.000 description 1
- LPUIZMWLTWEMIK-DHZHZOJOSA-N CCC(C1)(C(C2)CN1C(/C=C/c(cc1CC3)cnc1NC3=O)=O)C=C2c1ccccc1 Chemical compound CCC(C1)(C(C2)CN1C(/C=C/c(cc1CC3)cnc1NC3=O)=O)C=C2c1ccccc1 LPUIZMWLTWEMIK-DHZHZOJOSA-N 0.000 description 1
- YWKVFQPDXVHZCZ-ZZXKWVIFSA-N CCC(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O Chemical compound CCC(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O YWKVFQPDXVHZCZ-ZZXKWVIFSA-N 0.000 description 1
- VWLPXBOGRXQIPW-ZZXKWVIFSA-N CCOC(C(C1)=CC(C2)C1CN2C(/C=C/c1cc(CCC(N2)=O)c2nc1)=O)=O Chemical compound CCOC(C(C1)=CC(C2)C1CN2C(/C=C/c1cc(CCC(N2)=O)c2nc1)=O)=O VWLPXBOGRXQIPW-ZZXKWVIFSA-N 0.000 description 1
- PDKZHYXZLSECQY-ZZXKWVIFSA-N CN(C)C(C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=O Chemical compound CN(C)C(C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=O PDKZHYXZLSECQY-ZZXKWVIFSA-N 0.000 description 1
- DYOBLZXEGUUHDN-GORDUTHDSA-N COC(C1)CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O Chemical compound COC(C1)CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O DYOBLZXEGUUHDN-GORDUTHDSA-N 0.000 description 1
- SBOYOPATFOEOMK-RMKNXTFCSA-N COc(cccc1)c1C(C1)=CC(C2)C1CN2C(/C=C/c1cc(CCC(N2)=O)c2nc1)=O Chemical compound COc(cccc1)c1C(C1)=CC(C2)C1CN2C(/C=C/c1cc(CCC(N2)=O)c2nc1)=O SBOYOPATFOEOMK-RMKNXTFCSA-N 0.000 description 1
- JUUXATXKFOETIP-ZZXKWVIFSA-N C[O](C)c1c(C(C2)=CC(C3)C2CN3C(/C=C/c(cc2CC3)cnc2NC3=O)=O)[s]cc1 Chemical compound C[O](C)c1c(C(C2)=CC(C3)C2CN3C(/C=C/c(cc2CC3)cnc2NC3=O)=O)[s]cc1 JUUXATXKFOETIP-ZZXKWVIFSA-N 0.000 description 1
- MVRPXJRQLWERQS-GORDUTHDSA-N Cc1c(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)[s]cc1 Chemical compound Cc1c(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)[s]cc1 MVRPXJRQLWERQS-GORDUTHDSA-N 0.000 description 1
- ZWNANOGHPZFMMK-GORDUTHDSA-N Cc1c[s]c(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)c1 Chemical compound Cc1c[s]c(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)c1 ZWNANOGHPZFMMK-GORDUTHDSA-N 0.000 description 1
- ZJCBSKDBWAGQPE-XVNBXDOJSA-N Cc1ccc(C(C2)=CC(C3)C2CN3C(/C=C/c(cc2CC3)cnc2NC3=O)=O)[s]1 Chemical compound Cc1ccc(C(C2)=CC(C3)C2CN3C(/C=C/c(cc2CC3)cnc2NC3=O)=O)[s]1 ZJCBSKDBWAGQPE-XVNBXDOJSA-N 0.000 description 1
- DOMUSBOTBVCQAW-XVNBXDOJSA-N Cc1ccc(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)[o]1 Chemical compound Cc1ccc(C(C2)=CC(C3)C2CN3C(/C=C/c2cc(CCC(N3)=O)c3nc2)=O)[o]1 DOMUSBOTBVCQAW-XVNBXDOJSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CFQIXZOSNFEDDD-DAFODLJHSA-N NC(C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=O Chemical compound NC(C(C1)=CC(C2)C1CN2C(/C=C/c(cc1CC2)cnc1NC2=O)=O)=O CFQIXZOSNFEDDD-DAFODLJHSA-N 0.000 description 1
- SWLJRNNXXOGSTO-BWNRDHJKSA-N O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(C1)C[C@@H](C2)[C@H]1CN2c1cc(Cl)ccc1 Chemical compound O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(C1)C[C@@H](C2)[C@H]1CN2c1cc(Cl)ccc1 SWLJRNNXXOGSTO-BWNRDHJKSA-N 0.000 description 1
- WUTXJXPXEUNJKS-QFDSWDFVSA-N O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(C1)C[C@@H](C2)[C@H]1CN2c1ccccc1 Chemical compound O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(C1)C[C@@H](C2)[C@H]1CN2c1ccccc1 WUTXJXPXEUNJKS-QFDSWDFVSA-N 0.000 description 1
- XDTKMCDFAJHPSD-LZCJLJQNSA-N O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(CC1C2)CC1C=C2c([s]1)ccc1Cl Chemical compound O=C(/C=C/c(cc1CC2)cnc1NC2=O)N(CC1C2)CC1C=C2c([s]1)ccc1Cl XDTKMCDFAJHPSD-LZCJLJQNSA-N 0.000 description 1
- PJTZAENKRJVGMP-DAFODLJHSA-N O=C(/C=C/c(cc1CC2)cnc1NC2=O)N1CC(CC(C2)(F)F)C2C1 Chemical compound O=C(/C=C/c(cc1CC2)cnc1NC2=O)N1CC(CC(C2)(F)F)C2C1 PJTZAENKRJVGMP-DAFODLJHSA-N 0.000 description 1
- BJZMKFZXAANTDL-DAFODLJHSA-N O=C(/C=C/c(cc1CC2)cnc1NC2=O)N1CC(CC(C2)[n]3nccn3)C2C1 Chemical compound O=C(/C=C/c(cc1CC2)cnc1NC2=O)N1CC(CC(C2)[n]3nccn3)C2C1 BJZMKFZXAANTDL-DAFODLJHSA-N 0.000 description 1
- HAMICPIHVXUBQG-PBPLUFFFSA-N O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(C1)C[C@@H](C2)[C@H]1CN2c(cc1)ccc1Cl Chemical compound O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(C1)C[C@@H](C2)[C@H]1CN2c(cc1)ccc1Cl HAMICPIHVXUBQG-PBPLUFFFSA-N 0.000 description 1
- CTVSGEOIQUCIMM-ZZXKWVIFSA-N O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c(cccn1)c1Cl Chemical compound O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c(cccn1)c1Cl CTVSGEOIQUCIMM-ZZXKWVIFSA-N 0.000 description 1
- CPVUMKGKEKLEIZ-DAFODLJHSA-N O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c1cncnc1 Chemical compound O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c1cncnc1 CPVUMKGKEKLEIZ-DAFODLJHSA-N 0.000 description 1
- HBKQZVDRMAOABP-DAFODLJHSA-N O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC(CC(C2)[n]3nncc3)C2C1 Chemical compound O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC(CC(C2)[n]3nncc3)C2C1 HBKQZVDRMAOABP-DAFODLJHSA-N 0.000 description 1
- ZFZNZDGDMAYISN-QPJJXVBHSA-N O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC2C=CCC2C1 Chemical compound O=C(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC2C=CCC2C1 ZFZNZDGDMAYISN-QPJJXVBHSA-N 0.000 description 1
- FCQCIKAMISGOKH-UHFFFAOYSA-N O=C(C#Cc1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c1ccccc1 Chemical compound O=C(C#Cc1cc(CCC(N2)=O)c2nc1)N(CC1C2)CC1C=C2c1ccccc1 FCQCIKAMISGOKH-UHFFFAOYSA-N 0.000 description 1
- BGBKVBRKZMWMIR-GORDUTHDSA-N OC(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC(CC(C2)[n]3nccc3)C2C1 Chemical compound OC(/C=C/c1cc(CCC(N2)=O)c2nc1)N1CC(CC(C2)[n]3nccc3)C2C1 BGBKVBRKZMWMIR-GORDUTHDSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119 | 2011-08-10 | ||
| EP11177119.2 | 2011-08-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524410A Division JP5921687B2 (ja) | 2011-08-10 | 2012-08-10 | 抗菌性シクロペンタ［ｃ］ピロール置換３，４−ジヒドロ−１ｈ−［１，８］−ナフチリジノン類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016190843A JP2016190843A (ja) | 2016-11-10 |
| JP2016190843A5 true JP2016190843A5 (enExample) | 2017-01-12 |
Family
ID=46650549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524410A Expired - Fee Related JP5921687B2 (ja) | 2011-08-10 | 2012-08-10 | 抗菌性シクロペンタ［ｃ］ピロール置換３，４−ジヒドロ−１ｈ−［１，８］−ナフチリジノン類 |
| JP2016079689A Withdrawn JP2016190843A (ja) | 2011-08-10 | 2016-04-12 | 抗菌性シクロペンタ［ｃ］ピロール置換３，４−ジヒドロ−１ｈ−［１，８］−ナフチリジノン類 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014524410A Expired - Fee Related JP5921687B2 (ja) | 2011-08-10 | 2012-08-10 | 抗菌性シクロペンタ［ｃ］ピロール置換３，４−ジヒドロ−１ｈ−［１，８］−ナフチリジノン類 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906923B2 (enExample) |
| EP (1) | EP2742045B1 (enExample) |
| JP (2) | JP5921687B2 (enExample) |
| KR (1) | KR101996862B1 (enExample) |
| CN (2) | CN105461684B (enExample) |
| AR (1) | AR087508A1 (enExample) |
| AU (1) | AU2012293621B2 (enExample) |
| BR (1) | BR112014003063B1 (enExample) |
| CA (1) | CA2842518C (enExample) |
| CL (1) | CL2014000289A1 (enExample) |
| DK (1) | DK2742045T3 (enExample) |
| EA (1) | EA201490438A1 (enExample) |
| ES (1) | ES2721658T3 (enExample) |
| HU (1) | HUE042978T2 (enExample) |
| IL (1) | IL230549A (enExample) |
| JO (1) | JO3611B1 (enExample) |
| MX (1) | MX348128B (enExample) |
| PE (1) | PE20141410A1 (enExample) |
| PH (1) | PH12014500317A1 (enExample) |
| TR (1) | TR201905537T4 (enExample) |
| TW (1) | TWI568731B (enExample) |
| UA (1) | UA111210C2 (enExample) |
| UY (1) | UY34253A (enExample) |
| WO (1) | WO2013021054A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| EP2742047B1 (en) | 2011-08-10 | 2021-05-12 | Janssen Sciences Ireland Unlimited Company | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| US9315522B2 (en) * | 2012-08-10 | 2016-04-19 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| EP3461827B1 (en) | 2013-09-26 | 2022-02-23 | Cadent Therapeutics, Inc. | Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| US11691967B2 (en) | 2018-03-12 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| FI3880675T3 (fi) | 2018-11-12 | 2024-12-09 | Debiopharm Int Sa | Antibioottiyhdisteitä, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia koostumuksia ja niiden käyttöjä |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| CA3212074A1 (en) * | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| AR025976A1 (es) | 1999-10-08 | 2002-12-26 | Affinium Pharm Inc | Inhibidores de fab i. |
| WO2001026654A1 (en) | 1999-10-08 | 2001-04-19 | Smithkline Beecham Corporation | Fab i inhibitors |
| EP1225894B1 (en) | 1999-10-08 | 2006-07-05 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| CA2444597A1 (en) | 2001-04-06 | 2002-10-06 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| CA2568914C (en) * | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| EP2687533B1 (en) * | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| US8263613B2 (en) * | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
| JP5816629B2 (ja) | 2009-11-18 | 2015-11-18 | ファブ ファーマ エスエーエス | 新規の複素環式アクリルアミド及び医薬としてのその使用 |
| JP2014524409A (ja) | 2011-07-29 | 2014-09-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Ｈｉｖの治療のための組成物および方法 |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| EP2742047B1 (en) | 2011-08-10 | 2021-05-12 | Janssen Sciences Ireland Unlimited Company | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| KR101996866B1 (ko) | 2011-08-10 | 2019-07-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균성 호모피페리디닐 치환 3,4-디하이드로-1h-[1,8]나프티리디논 |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en not_active Ceased
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja not_active Expired - Fee Related
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh not_active IP Right Cessation
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en not_active Ceased
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko not_active Expired - Fee Related
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/en active
- 2012-08-10 PH PH1/2014/500317A patent/PH12014500317A1/en unknown
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en not_active Expired - Fee Related
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2903288C (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2015500843A5 (enExample) | ||
| JP2009530345A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JP2014525420A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2011526283A5 (enExample) | ||
| JP2016519165A5 (enExample) | ||
| JP2013537198A5 (enExample) | ||
| JP2011516460A5 (enExample) | ||
| JP2012512863A5 (enExample) | ||
| JP2016510768A5 (enExample) | ||
| JP2013544854A5 (enExample) | ||
| JP2014510147A5 (enExample) | ||
| UA101305C2 (ru) | Антибактериальные производные хинолина | |
| JP2011526286A5 (enExample) | ||
| IN2014MN02364A (enExample) | ||
| JP2010514734A5 (enExample) | ||
| JO2725B1 (en) | Quinoline antibacterial derivatives | |
| JO2970B1 (en) | Quinoline antibacterial derivatives | |
| UA101307C2 (ru) | Антибактериальные производные хинолина | |
| IN2014MN02358A (enExample) | ||
| JP2015536993A5 (enExample) | ||
| JP2014074018A5 (enExample) |